{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:00:12Z","timestamp":1788537612578,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>While studies have explored the feasibility of switching between various thrombopoietin receptor agonists in treating immune thrombocytopenia (ITP), data on the switching from eltrombopag to hetrombopag remains scarce. This post-hoc analysis of a phase III hetrombopag trial aimed to assess the outcomes of ITP patients who switched from eltrombopag to hetrombopag. In the original phase III trial, patients initially randomized to the placebo group were switched to eltrombopag. Those who completed this 14-week eltrombopag were eligible to switch to a 24-week hetrombopag. Treatment response, defined as a platelet count of \u2265\u200950\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L, and safety were evaluated before and after the switch. Sixty-three patients who completed the 14-week eltrombopag and switched to hetrombopag were included in this post-hoc analysis. Response rates before and after the switch were 66.7% and 88.9%, respectively. Among those with pre-switching platelet counts below 30\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L, eight out of 12 patients (66.7%) responded, while eight out of nine patients (88.9%) with pre-switching platelet counts between 30\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L and 50\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L responded post-switching. Treatment-related adverse events were observed in 50.8% of patients during eltrombopag treatment and 38.1% during hetrombopag treatment. No severe adverse events were noted during hetrombopag treatment. Switching from eltrombopag to hetrombopag in ITP management appears to be effective and well-tolerated. Notably, hetrombopag yielded high response rates, even among patients who had previously shown limited response to eltrombopag. However, these observations need to be confirmed in future trials.<\/jats:p>","DOI":"10.1007\/s00277-024-05826-5","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T04:01:41Z","timestamp":1717646501000},"page":"2273-2281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial"],"prefix":"10.1007","volume":"103","author":[{"given":"Heng","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhou","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuliang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renchi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"issue":"10","key":"5826_CR1","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1056\/NEJMcp1810479","volume":"381","author":"N Cooper","year":"2019","unstructured":"Cooper N, Ghanima W (2019) Immune Thrombocytopenia. N Engl J Med 381(10):945\u2013955","journal-title":"N Engl J Med"},{"issue":"1","key":"5826_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-023-01401-z","volume":"16","author":"XG Liu","year":"2023","unstructured":"Liu XG, Hou Y, Hou M (2023) How we treat primary immune thrombocytopenia in adults. J Hematol Oncol 16(1):4","journal-title":"J Hematol Oncol"},{"issue":"8","key":"5826_CR3","first-page":"617","volume":"41","author":"Thrombosis","year":"2020","unstructured":"Thrombosis, S.o.H.C.M C (2020) [Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)]. Zhonghua Xue Ye Xue Za Zhi 41(8):617\u2013623","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"23","key":"5826_CR4","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C et al (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3(23):3829\u20133866","journal-title":"Blood Adv"},{"issue":"6","key":"5826_CR5","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","volume":"104","author":"W Ghanima","year":"2019","unstructured":"Ghanima W et al (2019) Thrombopoietin receptor agonists: ten years later. Haematologica 104(6):1112\u20131123","journal-title":"Haematologica"},{"issue":"10","key":"5826_CR6","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","volume":"113","author":"JB Bussel","year":"2009","unstructured":"Bussel JB et al (2009) Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113(10):2161\u20132171","journal-title":"Blood"},{"issue":"22","key":"5826_CR7","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa073275","volume":"357","author":"JB Bussel","year":"2007","unstructured":"Bussel JB et al (2007) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357(22):2237\u20132247","journal-title":"N Engl J Med"},{"issue":"25","key":"5826_CR8","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","volume":"123","author":"JB Bussel","year":"2014","unstructured":"Bussel JB et al (2014) A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 123(25):3887\u20133894","journal-title":"Blood"},{"issue":"1","key":"5826_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-021-01047-9","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H et al (2021) A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. J Hematol Oncol 14(1):37","journal-title":"J Hematol Oncol"},{"issue":"6","key":"5826_CR10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/14656566.2023.2198089","volume":"24","author":"T Li","year":"2023","unstructured":"Li T et al (2023) Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis. Expert Opin Pharmacother 24(6):763\u2013774","journal-title":"Expert Opin Pharmacother"},{"issue":"13","key":"5826_CR11","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s40265-021-01575-1","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY (2021) Hetrombopag: first approval. Drugs 81(13):1581\u20131585","journal-title":"Drugs"},{"issue":"11","key":"5826_CR12","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1111\/jcmm.13809","volume":"22","author":"C Xie","year":"2018","unstructured":"Xie C et al (2018) Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. J Cell Mol Med 22(11):5367\u20135377","journal-title":"J Cell Mol Med"},{"issue":"5","key":"5826_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/bcpt.12815","volume":"121","author":"L Zheng","year":"2017","unstructured":"Zheng L et al (2017) Safety, Pharmacokinetics and Pharmacodynamics of Hetrombopag Olamine, a novel TPO-R agonist, in healthy individuals. Basic Clin Pharmacol Toxicol 121(5):414\u2013422","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"5826_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/bjh.13266","volume":"169","author":"JR Gonzalez-Porras","year":"2015","unstructured":"Gonzalez-Porras JR et al (2015) Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol 169(1):111\u2013116","journal-title":"Br J Haematol"},{"issue":"3","key":"5826_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/bjh.18081","volume":"197","author":"H Al-Samkari","year":"2022","unstructured":"Al-Samkari H et al (2022) Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study. Br J Haematol 197(3):359\u2013366","journal-title":"Br J Haematol"},{"issue":"7","key":"5826_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1182\/blood.2021010735","volume":"138","author":"F Palandri","year":"2021","unstructured":"Palandri F et al (2021) Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. Blood 138(7):571\u2013583","journal-title":"Blood"},{"issue":"7","key":"5826_CR17","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1182\/blood-2012-11-465575","volume":"121","author":"G D\u2019Arena","year":"2013","unstructured":"D\u2019Arena G et al (2013) No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. Blood 121(7):1240\u20131242","journal-title":"Blood"},{"issue":"3","key":"5826_CR18","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/jth.15602","volume":"20","author":"H Mei","year":"2022","unstructured":"Mei H et al (2022) Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: results from an open-label extension study. J Thromb Haemost 20(3):716\u2013728","journal-title":"J Thromb Haemost"},{"key":"5826_CR19","doi-asserted-by":"publisher","first-page":"204062071983790","DOI":"10.1177\/2040620719837906","volume":"10","author":"JR Gonzalez-Porras","year":"2019","unstructured":"Gonzalez-Porras JR, Godeau B, Carpenedo M (2019) Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia. Ther Adv Hematol 10:2040620719837906","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"5826_CR20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1365-2710.2012.01353.x","volume":"37","author":"T Aoki","year":"2012","unstructured":"Aoki T et al (2012) Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. J Clin Pharm Ther 37(6):729\u2013732","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"5826_CR21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3324\/haematol.2012.074633","volume":"98","author":"M Khellaf","year":"2013","unstructured":"Khellaf M et al (2013) A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica 98(6):881\u2013887","journal-title":"Haematologica"},{"issue":"12","key":"5826_CR22","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3324\/haematol.2016.153668","volume":"101","author":"H Raslova","year":"2016","unstructured":"Raslova H, Vainchenker W, Plo I (2016) Eltrombopag, a potent stimulator of megakaryopoiesis. Haematologica 101(12):1443\u20131445","journal-title":"Haematologica"},{"issue":"12","key":"5826_CR23","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3324\/haematol.2016.146746","volume":"101","author":"CA Di Buduo","year":"2016","unstructured":"Di Buduo CA et al (2016) Revealing eltrombopag\u2019s promotion of human megakaryopoiesis through AKT\/ERK-dependent pathway activation. Haematologica 101(12):1479\u20131488","journal-title":"Haematologica"},{"key":"5826_CR24","doi-asserted-by":"crossref","unstructured":"Kolodny S et al (2023) PB2622: A prospective, open-label ongoing study of safety and treatment satisfaction in adult immune thrombocytopenia (ITP) subjects after switching to avatrombopag from eltrombopag or romiplostim. Hemasphere, 7(Suppl)","DOI":"10.1097\/01.HS9.0000977176.66781.66"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05826-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05826-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05826-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T16:07:39Z","timestamp":1720109259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05826-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["5826"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05826-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted with the approval of independent ethics committees or institutional review boards of all the study centers and in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients involved in the study provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"The study was registered at clinicaltrials.gov with the identifier NCT03222843.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}}]}}